SynthesisAsian Pacific journal of cancer prevention : APJCP2025
The Association Between Selenium Levels and Risk of Prostate Cancer: A Systematic Review and Meta-analysis of 16,964 Participants (1980-2024).
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies worldwide have explored the link between selenium levels and prostate cancer, yet their findings remain inconsistent. This systematic review and meta-analysis aimed to clarify this association by synthesizing results from analytical observational studies, including cohort and case-control studies. The insights from this meta-analysis could significantly impact healthcare decisions, clinical management, and treatment guideline updates.
methodThis study utilized a systematic review and meta-analysis approach, conducting a comprehensive literature search across international databases such as PubMed (Medline), Scopus, Web of Science, and Embase with relevant keywords. Articles were screened at the title, abstract, and full-text levels, followed by a quality assessment using the NOS checklist. Statistical analysis was performed using STATA version 17.
resultsAfter pooling data from eleven studies investigating the relationship between plasma or serum selenium and prostate cancer risk, findings indicated that higher selenium levels were associated with an 11% reduced risk of prostate cancer (RR= 0.89; 95% CI: 0.83 - 0.95; P-value= 0.03; I square= 34.46%). When selenium dosage was considered, with doses below 70 μg as the reference, individuals exposed to 130-160 μg exhibited a reduced cancer risk of 0.85 (RR= 0.85; 95% CI: 0.76 - 0.96; P-value= 0.18; I square= 27.37%), while those exposed to doses of 160 μg or higher had an RR of 0.89 (95% CI: 0.69 - 1.15; P-value= 0.19; I square= 0.00%). Additionally, an inverse relationship was found between selenium levels in toenails and prostate cancer risk (RR= 0.61; 95% CI: 0.50 - 0.75; P-value= 0.63; I square= 0.00%) and advanced prostate cancer (RR= 0.73; 95% CI: 0.67 - 0.80; P-value= 0.00; I square= 69.79%).
conclusionThis meta-analysis suggests that selenium may have a protective effect against prostate cancer. Strategies to optimize selenium intake should be considered for prostate cancer prevention and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.